Among the BC patients positive for BRCA1-, three (100%) had a triple-negative BC whereas, among those positive for BRCA2- tumours, two were triple-negative BC (40%), one was Luminal B/HER2- (20%) and two were Luminal B/HER2+ (40%, Figure 6B). This evidence concerns the gene BRCA2 and breast cancer.